A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2019
Price : $35 *
At a glance
- Drugs RP G28 (Primary)
- Indications Lactose intolerance
- Focus Registrational; Therapeutic Use
- Acronyms Liberatus
- Sponsors Ritter Pharmaceuticals
- 12 Sep 2019 Primary endpoint (Change from baseline of the Lactose Intolerance (LI) symptom composite score compared to placebo) has not been met, according to a Ritter Pharmaceuticals media release.
- 12 Sep 2019 Top-line results presented in a Ritter Pharmaceuticals media release.
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History